Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma(R/R DLBCL)

Next Previous
Trial Profile

A Phase II Randomized, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma(R/R DLBCL)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HMPL-760 (Primary) ; Gemcitabine; Oxaliplatin; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors HUTCHMED

Most Recent Events

  • 06 Jun 2025 Status changed from recruiting to active, no longer recruiting.
  • 19 Nov 2024 Status changed from not yet recruiting to recruiting.
  • 30 Sep 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top